HYPNARA™ and related technologies are not yet FDA cleared or Approved

Minimally invasive airway solutions for
a post-CPAP era,

Minimally invasive airway solutions for
a post-CPAP era,

One‑time, in‑office palatal implant to intelligent oral devices and monitoring, Somnus Technologies is building a platform for simple, durable airway therapies.

One‑time, in‑office palatal implant to intelligent oral devices and monitoring, Somnus Technologies is building a platform for simple, durable airway therapies.

Contact sales

Contact sales

Who we serve

HYPNARA™ palatal implant

Who we serve

HYPNARA™ is a palatal implant system designed to be placed in a 15–20-minute, office‑based procedure under local anesthesia to address snoring and mild–moderate OSA in appropriately selected patients.

Shape

Office-Based Care

Performed under local anesthesia with no hospital stay required.

Precision Delivery

Shape

Three to five small implants placed using a depth-controlled modern system.

Shape

Tissue Stabilization

Designed to stiffen palatal tissue, reducing vibration and airway collapse.

Modern Evolution

Shape

Updated materials, improved ergonomics, and a streamlined commercial model.

Improved ergonomics, & a streamlined commercial model.

Logo Icon

Historical data

Clinical foundation

Who we serve

Palatal implants are supported by a body of historical clinical literature. Historical studies of earlier palatal implant systems have demonstrated:

Snoring

Significant reductions in snoring severity and bed-partner-reported snoring scores over follow-up.

Sleepiness

Improvements in daytime sleepiness scores over 12-month and longer follow-up periods.

AHI

Approximately 50% reduction in apnea–hypopnea index in selected mild–moderate OSA patients.

Safety

Favorable safety profiles with low extrusion rates and no reported serious airway obstruction events.

These results come from earlier palatal implant systems and inform our design assumptions; they do not represent clinical outcomes for HYPNARA, which remains under evaluation and regulatory review. Drug-induced sleep endoscopy and related studies consistently show that the soft palate is involved in the vast majority of OSA cases, making palate-focused solutions highly relevant for this population.

Download Clinical Summary

Problem solving

GLP‑1s and our focus

GLP‑1s and
our focus

Metabolic therapies can support weight loss, but upper-airway structure typically requires direct intervention.

Metabolic therapies can support weight loss, but upper-airway structure typically requires direct intervention.

GLP‑1 medications can reduce OSA severity in some adults with obesity by driving weight loss and improving related comorbidities. They are an important option, but they do not directly remodel or reinforce upper‑airway structures, and not all patients with OSA are obese. Somnus Technologies is developing minimally invasive implants and smart oral devices that act locally on airway anatomy and function—intended to complement, not replace, metabolic therapies when they are appropriate.

0

%

Weight-Driven Effect

0

%

Airway-Focused Design

GLP‑1 medications can reduce OSA severity in some adults with obesity by driving weight loss and improving related comorbidities. They are an important option, but they do not directly remodel or reinforce upper‑airway structures, and not all patients with OSA are obese. Somnus Technologies is developing minimally invasive implants and smart oral devices that act locally on airway anatomy and function—intended to complement, not replace, metabolic therapies when they are appropriate.

0

%

Weight-Driven Effect

0

%

Airway-Focused Design

MORPHEX™

MORPHEX™ and
smart oral devices

MORPHEX™ and
smart oral devices

Beyond HYPNARA™, we are developing MORPHEX™ AI, a smart oral device platform and software stack designed to extend airway management into everyday life.

Beyond HYPNARA™, we are developing MORPHEX™ AI, a smart oral device platform and software stack designed to extend airway management into everyday life.

Devices

Sensor-integrated mandibular devices for real-time respiratory and performance monitoring.

  • Adherence Tracking

    Real-time usage monitoring.

  • Respiratory Insights

    Continuous breathing pattern analysis.

  • Treatment Efficacy

    Outcome performance over time.

  • Risk Detection

    Early risk signal detection.

  • Clinician Dashboard

    Clear actionable patient summaries.

  • AI Optimization

    Adaptive learning for outcomes.

Analytics

AI-driven analytics delivering clear, actionable insights into adherence, efficacy, and risk trends.

Pipeline

Pipeline concepts including youth sports airway monitoring and concussion safety applications.

Reach out anytime

IP and plattform strategy

IP and plattform strategy

Somnus Technologies is building defensible IP across implantable and wearable airway technologies, supporting a platform strategy spanning both surgical and conservative treatments.

Somnus Technologies is building defensible IP across implantable and wearable airway technologies, supporting a platform strategy spanning both surgical and conservative treatments.

Partnership & Investment

Partnership & Investment